NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.404) was uploaded to the NHS England Website on Tuesday 23, June 2026.
The following changes have been introduced:
Cemiplimab (CEM3)
To treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
NA (EPC2)
NA
Moved into routine commissioning - section B of list
Cemiplimab with platinum-based chemotherapy (CEM2)
For untreated advanced non-small-cell lung cancer where the following criteria have been met
Date moving into routine commissioning updated
Serplulimab in combination with carboplatin and etoposide (SER1) ## Serplulimab in combination with carboplatin and etoposide (SER1)
For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met
Date moving into routine commissioning updated Treatment criteria (#3) updated
Tisotumab vedotin (TISV1)
For treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment where the following criteria have been met
Date moving into routine commissioning updated
Atezolizumab in combination with carboplatin and etoposide (ATE7)
For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met
Treatment criterion (#1, 2, 3, 5 and 9) updated; Treatment criterion (#2, 4, 11 and 12) removed
Daratumumab in combination (with bortezomib, lenalidomide, and dexamethasone) (DAR6)
For UNTREATED multiple myeloma when a stem cell transplant is UNSUITABLE where the following criteria have been met
Treatment criteria (#8) updated
Durvalumab in combination with etoposide plus either carboplatin or cisplatin (DUR4)
For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met
Treatment criterion (#1, 2, 3, 5, 6 and 9) updated; Treatment criterion (#2, 4, 8, 12 and 13) removed
Serplulimab in combination with carboplatin and etoposide (SER1) ## Serplulimab in combination with carboplatin and etoposide (SER1)
For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met
Date moving into routine commissioning updated Treatment criteria (#3) updated
Zanidatamab (ZANI1)
For the treatment of HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment where the following criteria have been met
Treatment criteria (#2) corrected